ZVexNeo

ZVexNeo is a next‑generation cancer vaccine program built on Immune Design’s ZVex platform, a dendritic cell‑targeting, integration‑deficient lentiviral vector engineered to prime systemic cytotoxic T‑cell responses against tumor neoantigens. The ZVex platform is designed to deliver antigen-encoding sequences directly to dendritic cells in vivo, thereby inducing robust CD8+ T‑cell immunity, and ZVexNeo extends this concept to patient‑specific or shared tumor neoantigens identified through tumor genomic profiling.[3][11] Immune Design has described ZVexNeo as a neoantigen-focused extension of its oncology immunotherapy pipeline, intended to generate personalized or broadly applicable neoantigen vaccines that can be combined with checkpoint inhibitors to enhance anti‑tumor activity in multiple solid tumor settings.[3][11]